0001209191-20-060047.txt : 20201123 0001209191-20-060047.hdr.sgml : 20201123 20201123175854 ACCESSION NUMBER: 0001209191-20-060047 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201119 FILED AS OF DATE: 20201123 DATE AS OF CHANGE: 20201123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bradshaw Curt CENTRAL INDEX KEY: 0001794633 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38042 FILM NUMBER: 201339309 MAIL ADDRESS: STREET 1: 177 E COLORADO BLVD STREET 2: STE 700 CITY: PASADENA STATE: CA ZIP: 91105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARROWHEAD PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000879407 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460408024 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 177 E COLORADO BLVD STREET 2: SUITE 700 CITY: PASADENA STATE: CA ZIP: 91105 BUSINESS PHONE: 626-696-4702 MAIL ADDRESS: STREET 1: 177 E COLORADO BLVD STREET 2: SUITE 700 CITY: PASADENA STATE: CA ZIP: 91105 FORMER COMPANY: FORMER CONFORMED NAME: ARROWHEAD RESEARCH CORP DATE OF NAME CHANGE: 20040112 FORMER COMPANY: FORMER CONFORMED NAME: INTERACTIVE GROUP INC DATE OF NAME CHANGE: 20020509 FORMER COMPANY: FORMER CONFORMED NAME: INTERACTIVE INC DATE OF NAME CHANGE: 19940224 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-19 1 0000879407 ARROWHEAD PHARMACEUTICALS, INC. ARWR 0001794633 Bradshaw Curt 177 E. COLORADO BLVD SUITE 700 PASADENA CA 91105 0 1 0 0 Chief Scientific Officer Common Stock 2020-11-19 4 S 0 15625 69.39 D 15625 D Common Stock 2020-11-20 4 S 0 15625 68.73 D 0 D Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.16 to $69.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. 93,750 restricted stock units previously reported have been removed from this amount of securities beneficially owned due to forfeiture. /s/Curt Bradshaw 2020-11-23